

**Lantus Brand (insulin glargine)  
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

**URGENT**

MEMBER INFORMATION		
<b>LAST NAME:</b>	<b>FIRST NAME:</b>	
<b>PHONE NUMBER:</b>	<b>DATE OF BIRTH:</b>	
<b>STREET ADDRESS:</b>		
<b>CITY:</b>	<b>STATE:</b>	<b>ZIP CODE:</b>
<b>PATIENT INSURANCE ID NUMBER:</b>		

**MALE**    **FEMALE**   **HEIGHT (IN/CM):** \_\_\_\_\_   **WEIGHT (LB/KG):** \_\_\_\_\_   **ALLERGIES:** \_\_\_\_\_

**IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](http://PRIMETHERAPEUTICS.COM/NOPP)**

**PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):** \_\_\_\_\_  
**AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:** \_\_\_\_\_

PRESCRIBER INFORMATION			
<b>LAST NAME:</b>	<b>FIRST NAME:</b>		
<b>PRESCRIBER SPECIALTY:</b>	<b>EMAIL ADDRESS:</b>		
<b>NPI NUMBER:</b>	<b>DEA NUMBER:</b>		
<b>PHONE NUMBER:</b>	<b>FAX NUMBER:</b>		
<b>STREET ADDRESS:</b>			
<b>CITY:</b>	<b>STATE:</b>	<b>ZIP CODE:</b>	
<b>REQUESTER (if different than prescriber):</b>	<b>OFFICE CONTACT PERSON:</b>		

MEDICATION OR MEDICAL DISPENSING INFORMATION			
<b>MEDICATION NAME:</b>			
<b>DOSE/STRENGTH:</b>	<b>FREQUENCY:</b>	<b>LENGTH OF THERAPY/REFILLS:</b>	<b>QUANTITY:</b>
<input type="checkbox"/> <b>NEW THERAPY</b> <input type="checkbox"/> <b>RENEWAL</b> <b>IF RENEWAL: DATE THERAPY INITIATED:</b>			
<b>DURATION OF THERAPY (SPECIFIC DATES):</b>			

*Continued on next page*

**Lantus Brand (insulin glargine)  
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?**

YES (if yes, complete below)  NO

<b>MEDICATION/THERAPY</b> (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>
--	--	---

**2. LIST DIAGNOSES:**

**ICD-10:**

Diabetes  
 Other diagnosis: \_\_\_\_\_ ICD-10 Code(s): \_\_\_\_\_

**3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.**

Is patient going to be using drug in combination with a clinical trial?  Yes  No

Has patient had a 3-month trial with the generic / biosimilar insulin glargine product insulin glargine-yfgn AND/OR a 3-month trial of Rezvoglar(insulin glargine-aglr)?  Yes  No

**EITHER (A) OR (B) for all eligible patients who wish to bypass the 3-month trial with the generic /biosimilar insulin glargine product insulin glargine-yfgn and/or Rezvoglar(insulin glargine-aglr):**  
**(A)**

- Before patient will be approved for the branded Lantus product, does patient have an absolute contraindication why treatment with the generic/biosimilar insulin glargine-yfgn **AND/OR** Rezvoglar(insulin glargine-aglr) product cannot be continued (such as development of an allergic rash or difficulty breathing after using product)?  Yes  No

***If answer is "Yes" to the above question, a U.S. FDA MedWatch Voluntary Reporting Form for adverse drug reactions (FDA Form 3500) must be filed with the FDA and a copy of the completed form must be submitted as part of the prior authorization.***

- (B)**
- Does patient have an absolute contraindication to trial of the generic/biosimilar insulin glargine-yfgn **AND** Rezvoglar(insulin glargine-aglr) product(s), (such as a documented patient allergy to a known dye or binder or additive ***in all the available*** generic/biosimilar products), as specified by prescriber and corroborated in submitted chart documentation?  Yes  No

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

\_\_\_\_\_

\_\_\_\_\_

**Lantus Brand (insulin glargine)  
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO:** 800-424-7640

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201

P.O. Box 64811

St. Paul, MN 55164-0811

**Phone:** 877-228-7909